Related Experiment Videos
Hypervariable epitope construct: a synthetic immunogen that overcomes MHC restriction of antigen presentation
1Rand Afrikaans University, Aucklandpark, South Africa.
Molecular Immunology
|October 6, 1999
Summary
A novel hypervariable epitope construct (HEC) vaccine component overcomes major histocompatibility complex (MHC) restriction, improving immune responses. This peptide cocktail enhances T-cell proliferation and antibody binding compared to single peptides, suggesting broader vaccine efficacy.
Area of Science:
- Immunology
- Vaccinology
- Molecular Biology
Background:
- Major histocompatibility complex (MHC) molecules present antigens to T cells, but their peptide-binding limitations restrict vaccine effectiveness.
- Individual responses to vaccines vary due to MHC-restricted antigen presentation.
Purpose of the Study:
- To investigate if a heterogeneous peptide mixture, a hypervariable epitope construct (HEC), can overcome MHC restriction.
- To compare the immunogenicity of HEC with a conventional single sequence peptide (SSP).
Main Methods:
- Synthesized a heterogeneous cocktail of SIV envelope protein peptides (HEC) and a single peptide (SSP).
- Assessed T-cell proliferation and antibody responses in mouse models.
- Measured MHC class I molecule expression on RMA-S cells using confocal microscopy.
Main Results:
- HEC induced 15-fold greater T-cell proliferation than SSP.
- Antibodies from HEC immunization effectively bound viral antigens, unlike those from SSP.
- HECs upregulated MHC molecule expression by 30% more than SSPs.
Conclusions:
- HEC peptide cocktails can overcome MHC restriction in antigen presentation.
- HECs show potential as effective components for subunit vaccines to enhance immunogenicity in diverse populations.